Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001610618-24-000131
Filing Date
2024-10-02
Accepted
2024-10-02 17:19:12
Documents
1
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1727903945.html 4  
1 FORM 4 wk-form4_1727903945.xml 4 3931
  Complete submission text file 0001610618-24-000131.txt   5555
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Issuer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O BRAINSTORM CELL THERAPEUTICS, INC. 1325 AVENUE OF AMERICAS, 28TH FLR. NEW YORK NY 10019
Business Address
Shah Preetam (Reporting) CIK: 0001787403 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36912 | Film No.: 241348821